\-\ Texto\\:\\ \ \(0\)\
\-\ cbc\\ shows\\ an\\ mcv\\ of\\ 115\\.\ \(0\)\
\-\ parenteral\\ b12\\ injection\\ is\\ the\\ traditional\\ therapy\\ \\-\\ im\\ or\\ subq\\.\\ \\ however\\,\\ recent\\ reports\\ have\\ shown\\ both\\ safety\\ and\\ efficacy\\ for\\ high\\ dose\\ oral\\ b12\\ of\\ 1\\ milligram\\ \\(1\\,000\\ \\Â\\µg\\)\\ of\\ vitamin\\ b12\\ consumed\\ daily\\.\ \(0\)\
\-\ http\\:\\/\\/www\\.cdc\\.gov\\/ncbddd\\/b12\\/patients\\.html\ \(1\)\
\-\ increased\\ t2\\ signal\\ in\\ the\\ dorsal\\ columns\\ of\\ the\\ spinal\\ cord\\ \\(bilateral\\)\ \(0\)\
\-\ vitamin\\ b12\\ deficiency\\ \\(sub\\-acute\\ combined\\ degeneration\\)\ \(0\)\
\-\ subacute\\ combined\\ degeneration\ \(1\)\
\-\ lightning\\ strike\\ to\\ upper\\ body\ \(1\)\
\-\ no2\\ toxicity\ \(0\)\
\-\ hiv\\ myelopathy\ \(0\)\
\-\ spinal\\ dural\\ av\\ fistula\ \(0\)\
\-\ transverse\\ myelitis\ \(14\)\
\-\ multiple\\ sclerosis\ \(41\)\
\-\ radiation\ \(402\)\
\-\ leptomeningeal\\ carcinomatosis\ \(1\)\
\-\ compressive\\ myelopathy\ \(1\)\
\-\ 60\\ y\\/o\\ man\\ with\\ rapid\\ onset\\ of\\ gait\\ ataxia\\ and\\ loss\\ of\\ proprioception\\.\\ he\\ had\\ shoulder\\ surgery\\ 2\\ weeks\\ prior\\ and\\ received\\ nitrous\\ oxide\\ anesthesia\\.\ \(0\)\
\-\ this\\ patient\\ had\\ nitrous\\ oxide\\ anesthesia\\ for\\ shoulder\\ surgery\\ a\\ few\\ months\\ prior\\ to\\ admission\\.\\ he\\ also\\ had\\ egd\\ \\(esophago\\-gastro\\-duodenoscopy\\)\\ that\\ showed\\ an\\ atrophic\\ gastritis\\.\\ on\\ his\\ cbc\\ there\\ was\\ a\\ macrocytosis\\ with\\ an\\ mcv\\ of\\ 115\\ \\(normal\\ 80\\-100\\)\\ \\.\\ his\\ serum\\ b12\\ level\\ was\\ found\\ to\\ be\\ 42\\,\\ with\\ a\\ normal\\ range\\ of\\ 190\\-900\\.\\ he\\ was\\ started\\ on\\ vitamin\\ b12\\ injections\\ and\\ his\\ neurologic\\ status\\ began\\ to\\ gradually\\ improve\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ b12\\:\\ 0\\.20107692185930334\ \(0\)\
\-\ nitrous\\:\\ 0\\.08081961436225425\ \(0\)\
\-\ oxide\\:\\ 0\\.07678513567461083\ \(0\)\
\-\ vitamin\\:\\ 0\\.07509445955295876\ \(0\)\
\-\ myelopathy\\:\\ 0\\.06077082808820187\ \(0\)\
\-\ mcv\\:\\ 0\\.05742284563425945\ \(0\)\
\-\ anesthesia\\:\\ 0\\.056517653811316904\ \(0\)\
\-\ combined\\:\\ 0\\.0469768543457154\ \(0\)\
\-\ 115\\.\\:\\ 0\\.043858300616748745\ \(0\)\
\-\ subq\\:\\ 0\\.043858300616748745\ \(0\)\
\-\ milligram\\:\\ 0\\.043858300616748745\ \(0\)\
\-\ \\Â\\µg\\:\\ 0\\.043858300616748745\ \(0\)\
\-\ \\/\\/www\\.cdc\\.gov\\/ncbddd\\/b12\\/patients\\.html\\:\\ 0\\.043858300616748745\ \(0\)\
\-\ esophago\\-gastro\\-duodenoscopy\\:\\ 0\\.043858300616748745\ \(0\)\
\-\ macrocytosis\\:\\ 0\\.043858300616748745\ \(0\)\
\-\ 80\\-100\\:\\ 0\\.043858300616748745\ \(0\)\
\-\ 190\\-900\\.\\:\\ 0\\.043858300616748745\ \(0\)\
\-\ degeneration\\:\\ 0\\.0431659861640626\ \(0\)\
\-\ consumed\\:\\ 0\\.040409807181127126\ \(0\)\
\-\ lightning\\:\\ 0\\.040409807181127126\ \(0\)\
\-\ no2\\:\\ 0\\.040409807181127126\ \(0\)\
\-\ cbc\\:\\ 0\\.03799309602191426\ \(0\)\
\-\ strike\\:\\ 0\\.03696131374550551\ \(0\)\
\-\ his\\:\\ 0\\.03675953772607361\ \(0\)\
\-\ he\\:\\ 0\\.03558488570198536\ \(0\)\
\-\ 1\\,000\\:\\ 0\\.034944074401683796\ \(0\)\
\-\ shoulder\\:\\ 0\\.034277416874018266\ \(0\)\
\-\ im\\:\\ 0\\.034177155596573056\ \(0\)\
\-\ columns\\:\\ 0\\.034177155596573056\ \(0\)\
\-\ sub\\-acute\\:\\ 0\\.034177155596573056\ \(0\)\
\-\ parenteral\\:\\ 0\\.03292683505786208\ \(0\)\
\-\ 115\\:\\ 0\\.03292683505786208\ \(0\)\
\-\ safety\\:\\ 0\\.03192847338889616\ \(0\)\
\-\ proprioception\\:\\ 0\\.03149558096606218\ \(0\)\
\-\ traditional\\:\\ 0\\.031097358539825676\ \(0\)\
\-\ gastritis\\:\\ 0\\.031097358539825676\ \(0\)\
\-\ spinal\\:\\ 0\\.03044553443163767\ \(0\)\
\-\ efficacy\\:\\ 0\\.029762711840349662\ \(0\)\
\-\ toxicity\\:\\ 0\\.029762711840349662\ \(0\)\
\-\ myelitis\\:\\ 0\\.029762711840349662\ \(0\)\
\-\ egd\\:\\ 0\\.02895415995230103\ \(0\)\
\-\ atrophic\\:\\ 0\\.028711422817129725\ \(0\)\
\-\ had\\:\\ 0\\.027520146555831466\ \(0\)\
\-\ av\\:\\ 0\\.026773787161598766\ \(0\)\
\-\ injections\\:\\ 0\\.026462740609452823\ \(0\)\
\-\ compressive\\:\\ 0\\.026314218404728043\ \(0\)\
\-\ carcinomatosis\\:\\ 0\\.026029848186618847\ \(0\)\
\-\ leptomeningeal\\:\\ 0\\.025262929381508106\ \(0\)\
\-\ gradually\\:\\ 0\\.024703337424161392\ \(0\)\
\-\ hiv\\:\\ 0\\.023572044676919295\ \(0\)\
\-\ deficiency\\:\\ 0\\.022939431863559862\ \(0\)\
\-\ ataxia\\:\\ 0\\.02272150836774696\ \(0\)\
\-\ improve\\:\\ 0\\.022650938044403893\ \(0\)\
\-\ dose\\:\\ 0\\.022247328368720468\ \(0\)\
\-\ daily\\:\\ 0\\.021995369498975417\ \(0\)\
\-\ prior\\:\\ 0\\.021831967882610583\ \(0\)\
\-\ subacute\\:\\ 0\\.021814435945886487\ \(0\)\
\-\ dorsal\\:\\ 0\\.021639852265233406\ \(0\)\
\-\ 42\\:\\ 0\\.021526776389225663\ \(0\)\
\-\ began\\:\\ 0\\.021526776389225663\ \(0\)\
\-\ rapid\\:\\ 0\\.021471187829035985\ \(0\)\
\-\ fistula\\:\\ 0\\.02084848562528471\ \(0\)\
\-\ surgery\\:\\ 0\\.02064675685930622\ \(0\)\
\-\ dural\\:\\ 0\\.020610395967684537\ \(0\)\
\-\ serum\\:\\ 0\\.02051826140167838\ \(0\)\
\-\ injection\\:\\ 0\\.01983683923713531\ \(0\)\
\-\ gait\\:\\ 0\\.019797196602064776\ \(0\)\
\-\ received\\:\\ 0\\.019757867350785607\ \(0\)\
\-\ few\\:\\ 0\\.01913286131537561\ \(0\)\
\-\ started\\:\\ 0\\.01896304536328875\ \(0\)\
\-\ admission\\:\\ 0\\.01873463888913911\ \(0\)\
\-\ 60\\:\\ 0\\.0185468760633538\ \(0\)\
\-\ \\(\\:\\ 0\\.017969197170245286\ \(0\)\
\-\ oral\\:\\ 0\\.017913346598793595\ \(0\)\
\-\ neurologic\\:\\ 0\\.017753703242815982\ \(0\)\
\-\ \\)\\:\\ 0\\.017749693833664308\ \(0\)\
\-\ an\\:\\ 0\\.01763678901917507\ \(0\)\
\-\ reports\\:\\ 0\\.017138708437009133\ \(0\)\
\-\ range\\:\\ 0\\.017115621971553894\ \(0\)\
\-\ shown\\:\\ 0\\.017046998478358194\ \(0\)\
\-\ transverse\\:\\ 0\\.017046998478358194\ \(0\)\
\-\ cord\\:\\ 0\\.01615509413037513\ \(0\)\
\-\ http\\:\\ 0\\.016098450736220276\ \(0\)\
\-\ sclerosis\\:\\ 0\\.015270225041922113\ \(0\)\
\-\ status\\:\\ 0\\.015175757816824146\ \(0\)\
\-\ was\\:\\ 0\\.014750410779308758\ \(0\)\
\-\ recent\\:\\ 0\\.014292134571342274\ \(0\)\
\-\ radiation\\:\\ 0\\.013951498754041475\ \(0\)\
\-\ showed\\:\\ 0\\.013939319740913914\ \(0\)\
\-\ body\\:\\ 0\\.013807282152682012\ \(0\)\
\-\ onset\\:\\ 0\\.0134200060991301\ \(0\)\
\-\ found\\:\\ 0\\.013398137385333892\ \(0\)\
\-\ normal\\:\\ 0\\.01332947716019006\ \(0\)\
\-\ loss\\:\\ 0\\.012340617773474824\ \(0\)\
\-\ level\\:\\ 0\\.012253179242024537\ \(0\)\
\-\ weeks\\:\\ 0\\.012066058492045513\ \(0\)\
\-\ t2\\:\\ 0\\.012032779944031602\ \(0\)\
\-\ however\\:\\ 0\\.011837652017895873\ \(0\)\
\-\ y\\/o\\:\\ 0\\.011774273780197218\ \(0\)\
\-\ shows\\:\\ 0\\.011688426366810343\ \(0\)\
\-\ high\\:\\ 0\\.011634557517795102\ \(0\)\
\-\ months\\:\\ 0\\.011611648232288892\ \(0\)\
\-\ therapy\\:\\ 0\\.011366372120600064\ \(0\)\
\-\ signal\\:\\ 0\\.01120932502623273\ \(0\)\
\-\ both\\:\\ 0\\.010856716371572744\ \(0\)\
\-\ increased\\:\\ 0\\.010400421799998286\ \(0\)\
\-\ bilateral\\:\\ 0\\.01031750114086788\ \(0\)\
\-\ upper\\:\\ 0\\.01025910699188417\ \(0\)\
\-\ 1\\:\\ 0\\.010116051581889088\ \(0\)\
\-\ man\\:\\ 0\\.010054387279054722\ \(0\)\
\-\ have\\:\\ 0\\.009206159593856178\ \(0\)\
\-\ 2\\:\\ 0\\.009154748738858439\ \(0\)\
\-\ \\-\\:\\ 0\\.009113076908996834\ \(0\)\
\-\ multiple\\:\\ 0\\.008954258723777458\ \(0\)\
\-\ to\\:\\ 0\\.00849886782971117\ \(0\)\
\-\ also\\:\\ 0\\.00838119200830921\ \(0\)\
\-\ that\\:\\ 0\\.007343187704272753\ \(0\)\
\-\ for\\:\\ 0\\.0072548074491812446\ \(0\)\
\-\ on\\:\\ 0\\.007202895645427145\ \(0\)\
\-\ be\\:\\ 0\\.006556003598726015\ \(0\)\
\-\ there\\:\\ 0\\.006326943066989993\ \(0\)\
\-\ a\\:\\ 0\\.005919400027143302\ \(0\)\
\-\ \\:\\:\\ 0\\.005623257790998333\ \(0\)\
\-\ or\\:\\ 0\\.004982700243600535\ \(0\)\
\-\ this\\:\\ 0\\.004781777180667328\ \(0\)\
\-\ of\\:\\ 0\\.004636967195939838\ \(0\)\
\-\ patient\\:\\ 0\\.00426165139759397\ \(0\)\
\-\ and\\:\\ 0\\.0035822687707904167\ \(0\)\
\-\ is\\:\\ 0\\.002797466559127988\ \(0\)\
\-\ \\,\\:\\ 0\\.002693632492709327\ \(0\)\
\-\ in\\:\\ 0\\.002096503632538582\ \(0\)\
\-\ the\\:\\ 0\\.002063422159755609\ \(0\)\
\-\ with\\:\\ 0\\.0017463309864162648\ \(0\)\
\-\ \\.\\:\\ 0\\.0014129168595958717\ \(0\)\
